Cardiologists Urge Enhanced Safety Measures for Gene Editing in Common Diseases

A new perspective in JAMA Internal Medicine, authored by University of Michigan Health cardiologists, emphasizes the need for stronger safeguards as gene editing therapies expand from rare genetic disorders to prevalent conditions like heart disease, obesity, and diabetes. They propose strategies and five key questions to evaluate the justification for genomic therapy, stressing that safety standards must increase for broader patient populations.